The developer of epigenetic medicine, based on Whitehead Institute research, pulled in funding through a round led by founding investor Flagship Pioneering.
Omega Therapeutics, a US-based epigenetic medicine developer utilising research from Whitehead Institute, closed its series C round at $126m on Tuesday.
Company builder and venture capital firm Flagship Pioneering led the round, which also featured investment and financial services firm, Fidelity, Invus, Cowen, Point72, Logos Capital, Mirae Asset Capital, funds and accounts managed by BlackRock and undisclosed new and existing investors.
Omega was founded in 2017 by Flagship Pioneering and is developing treatments for medical conditions such as…
